
Health Dictionary
Reliable, easy-to-read patient information on common medical conditions — written in plain language, free of jargon, and grounded in current evidence. Browse the most frequent diagnoses, understand what they mean for everyday life, and learn which steps and questions help you have a focused conversation with your doctor.
Osteosarcoma biopsy
Introduction
Overview
Overview
Biopsy of osteosarcoma is important for confirming the diagnosis and the determining histologic subtype. Biopsy may be performed percutaneously with either a fine-needle, or wide-bore needle, or through a formal incision.
Biopsy
Biopsy
- Biopsy of osteosarcoma is important for confirming the diagnosis and the determining histologic subtype.
- Biopsy procedures include:[1][2][3][4]
- Needle biopsy
- Percutaneously with either a fine-needle, or a wide-bore needle
- Surgical biopsy
- Through a formal incision
- Needle biopsy
- More invasive methods carry a higher risk of complications and contamination of tissue planes.
- Each year 30% of patients lose their limbs through inappropriate biopsy site and technique.
- In principle, biopsies should be performed at a tumor center by a specialist in tumor surgery.
- Inappropriate alignment of the biopsy or inadvertent contamination of soft tissues can render subsequent limb-preserving reconstructive surgery impossible.
References
References
- ↑ Moore DD, Luu HH (2014). “Osteosarcoma”. Cancer Treat. Res. 162: 65–92. doi:10.1007/978-3-319-07323-1_4. PMID 25070231.
- ↑ Ilaslan H, Schils J, Nageotte W, Lietman SA, Sundaram M (March 2010). “Clinical presentation and imaging of bone and soft-tissue sarcomas”. Cleve Clin J Med. 77 Suppl 1: S2–7. doi:10.3949/ccjm.77.s1.01. PMID 20179183.
- ↑ Wu PK, Chen WM, Lee OK, Chen CF, Huang CK, Chen TH (November 2010). “The prognosis for patients with osteosarcoma who have received prior manipulative therapy”. J Bone Joint Surg Br. 92 (11): 1580–5. doi:10.1302/0301-620X.92B11.24706. PMID 21037356.
- ↑ Obiedat H, Alrabadi N, Sultan E, Al Shatti M, Zihlif M (July 2018). “The effect of ERCC1 and ERCC2 gene polymorphysims on response to cisplatin based therapy in osteosarcoma patients”. BMC Med. Genet. 19 (1): 112. doi:10.1186/s12881-018-0627-4. PMC 6035436. PMID 29980176.
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Mohammadmain Rezazadehsaatlou[2].
